India hospital covid-19 pandemic doctor India

Pharma stocks are on fire, but domestic growth rates may taper in FY21

Reading now: 862
www.livemint.com

Domestic pharma’s growth rate this past year has been remarkable, proving to be a buffer against sluggish overseas sales. While other sectoral indices are in the red, the Nifty Pharma index gained about 14.4% year to date.

However, those looking for these growth rates to sustain may need to pencil in a deceleration in the home market. Domestic sales of products in chronic and acute therapies have been robust in March, although lower compared to February.

February’s sales growth stepped up 12.1%, and that of March climbed 8.9%. Analysts say sales were driven by some early buying in March, though not to the extent seen in February.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA